The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors.
Gerald Steven Falchook
Consultant or Advisory Role - EMD Serono
Honoraria - EMD Serono
Research Funding - EMD Serono
Other Remuneration - EMD Serono
David S. Hong
No relevant relationships to disclose
Hesham M. Amin
Research Funding - EMD Serono
Siqing Fu
No relevant relationships to disclose
Sarina Anne Piha-Paul
No relevant relationships to disclose
Filip Janku
No relevant relationships to disclose
J. Gabrielle Granda
No relevant relationships to disclose
Hongxia Zheng
Employment or Leadership Position - EMD Serono
Manfred B. Klevesath
Employment or Leadership Position - Merck KGaA
Karola Köhler
Consultant or Advisory Role - Merck KGaA
Friedhelm Bladt
Employment or Leadership Position - Merck KGaA
Andreas Johne
Employment or Leadership Position - Merck KGaA
Razelle Kurzrock
Research Funding - Merck Serono